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Hypervirulent Clostridium difficile strains, most notably BI/NAP1/027, have been increasingly
emerging in Western countries as local epidemics. We performed a prospective multicentre
observational study from December 2011 to May 2012 to identify recent incidences of toxigenic
culture-confirmed hospital-onset C. difficile infections (CDI) and their associated clinical
characteristics in South Korea. Patients suspected of having been suffering from CDI more than
48 h after admission and aged ¢20 years were prospectively enrolled and provided loose stool
specimens. Toxigenic C. difficile culture (anaerobic culture+toxin A/B/binary gene PCR) and
PCR ribotyping were performed in one central laboratory. We enrolled 98 toxigenic culture-
confirmed CDI-infected patients and 250 toxigenic culture-negative participants from three
hospitals. The incidence of toxigenic culture-confirmed hospital-onset CDI cases was 2.7 per
10000 patient-days. The percentage of severe CDI cases was relatively low at only 3.1%. UK
ribotype 018 was the predominant type (48.1%). There were no hypervirulent BI/NAP1/027
isolates identified. The independent risk factors for toxigenic culture-confirmed hospital-onset CDI
were invasive procedure (odds ratio (OR) 7.3, P50.003) and past CDI history within 3 months
(OR 28.5, P50.003). In conclusion, the incidence and severity of CDI in our study were not higher
than reported in Western countries.
INTRODUCTION
Clostridium difficile is a Gram-positive, spore-forming anaer-
obic bacterium that is emerging as an important ubiquitous
pathogen that causes classical healthcare-associated infec-
tions that range from mild self-limiting diarrhoea to life-
threatening severe pseudomembranous colitis (PMC), toxic
megacolon, bowel perforation, severe sepsis, and death
(Bartlett et al., 1978; Lo Vecchio & Zacur, 2012; Rubin et al.,
1995; Safdar, 2012). C. difficile is estimated to be responsible
for 10–25% of all cases of antibiotic-associated diarrhoea
and for almost all cases of PMC (Anand et al., 1994; Bartlett,
1994). Another clinical significance of C. difficile infection
(CDI) is its relatively high recurrence rate (5–47% of cases)
(Barbut et al., 2000; Bauer et al., 2011). CDI is a growing
concern worldwide, as it not only increases the duration
of time a patient is required to stay hospitalized, which
increases the associated cost to the hospital, but also causes
morbidity and mortality (Kyne et al., 2002).
C. difficile toxin A (308 kDa) is commonly referred to as
the enterotoxin, while toxin B (270 kDa) is referred to as
the cytotoxin. These toxins damage intestinal epithelial cells
and are the cause of the associated clinical illness (Kuehne
et al., 2010). Recently, hypervirulent strains, most notably
BI/NAP1/027, which is detectable by PCR ribotype 027, as it
produces binary toxin as well as PCR ribotype 078, have
been increasingly emerging in Western countries as local
Abbreviations: CDI, Clostridium difficile infection; CI, confidence interval;
EIA, enzyme immunoassay; IBD, inflammatory bowel disease; OR, odds
ratio; PMC, pseudomembranous colitis.
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epidemics (Bauer et al., 2011; Clements et al., 2010; Goorhuis
et al., 2008; Kim et al., 2011). These strains have resulted in a
change in CDI epidemiology and have also increased the
incidence and severity of CDI (Barbut et al., 2005; Freeman
et al., 2010; Gilca et al., 2010; Ricciardi et al., 2007).
The well-known risk factors for CDI that lead to clinically
apparent disease in adults include prolonged antimicrobial
therapy, hospitalization, malnutrition, previous gastro-
intestinal surgery, older age (¢65 years of age), and
increased duration of hospital stay (Freeman et al., 2010;
Lo Vecchio & Zacur, 2012). However, in recent years, the
epidemiology of CDI has shifted from almost exclusively
infecting elderly patients in whom the gut microbiota has
been disturbed by antibiotics to now infecting individuals
of all age groups with no recent antibiotic exposure, and
includes community-onset or -acquired CDI (Lessa et al.,
2012). In addition, inflammatory bowel disease (IBD), cystic
fibrosis and solid organ transplantation have emerged as
new risk factors for CDI (Lo Vecchio & Zacur, 2012;
Patriarchi et al., 2011).
It has been reported that the increased usage of broad-
spectrum antibiotics and the rate of antimicrobial resist-
ance in major hospital-acquired pathogens are high in
South Korea (Kim, 2005; Lee et al., 2006, 2011). However,
a local epidemic caused by hypervirulent strains of C.
difficile has not occurred until recently in South Korea, in
spite of the uncommon reports of PCR ribotype 027
infection (Kim et al., 2011, 2013a; Shin et al., 2012; Tae
et al., 2009). There are only a few reports of prospective
multicentre epidemiological studies on CDI in South
Korea. The objective of this study was to estimate the
incidence and to determine the risk factors of toxigenic
culture-confirmed hospital-onset CDI cases by studying
hospitalized adult patients in South Korea through a
multicentre prospective cohort.
METHODS
Study design. This prospective, multicentre observational, epide-
miological study was conducted in three university-affiliated tertiary
care centre hospitals in Seoul, South Korea, between December 2011
and May 2012. An individual who met both of the following criteria
was eligible for enrolment: (1) hospitalized adult patient¢20 years of
age and (2) clinically suspected of having CDI any time after the first
48 h of hospitalization, as evidenced by the passage of three or more
unformed or loose stools (diarrhoea) per day for more than 2 days
(Kyne et al., 2000; Zar et al., 2007). We excluded patients that were
currently taking laxatives or had loose stools that were definitely
associated with an enema. The final protocol was approved by each of
the applicable independent ethics committees prior to the start of the
trial. All participants were required to provide a written informed
consent form prior to being included in the study. This study was
registered at Clinicaltrials.gov (NCT01560832).
Loose stool samples of the enrolled patients were submitted to the
clinical microbiology laboratory of the associated hospital. These
samples were transferred in an airtight container (to allow for an
anaerobic environment) to a central laboratory (Severance Hospital,
Yonsei University College of Medicine), and the anaerobic culture
and enzyme immunoassay (EIA) for toxins A and B were performed
within 24 h after sample collection (Crobach et al., 2009). If C.
difficile was cultured from a stool sample, then PCR assays for toxins
A and B and the binary toxin genes, as well as PCR ribotyping assay,
were conducted.
Data collection. Patients were enrolled prospectively at each
site. Relevant clinical and laboratory data were obtained from the
electronic medical records and/or by prospectively interviewing the
patient or his/her legally responsible representative in order to
complete a standardized questionnaire. Information was obtained
regarding the symptoms experienced and the frequency of diarrhoea.
The electronic medical records were used to identify the demographic
variables, laboratory findings, comorbid diseases, and history of admis-
sion and antibiotic use. We categorized the invasive procedures into the
following seven types, with possible multiple selection in one patient:
urinary tract procedures including urinary catheter insertion, invasive
blood stream procedures including central catheter insertion and
haemodialysis and/or continuous renal replacement therapy, respir-
atory tract or pleural cavity procedures including endotracheal tube
insertion and mechanical ventilation, gastrointestinal surgery, non-
gastrointestinal surgery, non-surgical gastrointestinal tract procedures
including naso-gastric (Levin) tube insertion, and central nervous
system procedures including cerebrospinal fluid tapping. The total
number of patients admitted and the number of days each patient was
hospitalized during the entire study period were obtained by using each
hospital’s computerized database to assess the number of patient-days,
which was used for the calculation of the incidence of CDI.
Definitions. The CDI severity score was calculated for all of the
participants, with severe CDI being defined as when a patient has a
score greater than 2 (Zar et al., 2007). The criteria for a severity score
of 1 are: (1).60 years of age, (2) temperature.38.3 uC, (3) peripheral
white blood cell count .15 000 ml21, or (4) serum albumin level
,2.5 mg dl21 (Zar et al., 2007). The criteria for a severity score of 2 are:
(1) endoscopic evidence of PMC or (2) treatment in the intensive care
unit (Zar et al., 2007). Toxigenic culture-confirmed CDI was defined as
when a case has a positive result for the A/B and/or binary toxin gene
PCR test (i.e. A+B+CDT+, A+B+CDT2, A2B+CDT2) of an
anaerobically cultured colony of the C. difficile strain.
A hospital-onset case was defined as a patient with diarrhoea onset
more than 48 h after the time of admission to a hospital (Kyne et al.,
2000; Zar et al., 2007). The incidence rate of toxigenic culture-
confirmed CDI cases was expressed as the number of cases per
10 000 patient-days.
C. difficile anaerobic culture. A total of 348 fresh, non-duplicated
stool specimens were collected from patients with suspected CDI at the
three hospitals throughout the study period. Alcohol-shocked stool
specimens were cultured anaerobically on C. difficile selective agar
(CDSA; Becton Dickinson) for 48 h at 37 uC. Suspected C. difficile
colonies were used to make Gram-stained smears to observe the typical
morphology. Species were identified using the ATB 32A system
(bioMe´rieux).
Toxin analysis by EIA and PCR. The commercial C. difficile toxin A
& B EIA (VIDAS CDAB assay; bioMe´rieux) was performed according
to the manufacturer’s instructions. The EIA test results were
interpreted as positive, negative or equivocal for both toxins A and
B. Specimens with equivocal results were retested.
C. difficile toxin genes were detected by PCR as described previously
(Kato et al., 1998; Stubbs et al., 2000). The primer pairs used were
NK9/NK11 for the repetitive domain of the toxin A gene (tcdA rep),
NK104/NK105 for the toxin B gene (tcdB), cdtA pos/cdtA rev for the
C. difficile binary toxin A gene (cdtA), and cdtB pos/cdtB rev for the C.
difficile binary toxin B gene (cdtB) (Kato et al., 1998; Stubbs et al.,
2000; Terhes et al., 2004). The reference strains VPI 10463
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(A+B+CDT2), 3608/03 (A2B2CDT2), SE844 (A+B+CDT+), 48489
(CDT+), 1470 (A2B+CDT2) and UK078 were used as controls
(Alonso et al., 2005; Kim et al., 2010).
PCR ribotyping. PCR ribotyping was performed as previously
described with primers 59-CTGGGGTGAAGTCGTAACAAGG-39
(position 1445 to 1466 of the 16S rRNA gene) and 59-GCGCCCTT-
TGTAGCTTGACC-39 (position 20 to 1 of the 23S rRNA gene)
(Stubbs et al., 1999). The PCR ribotyping patterns were compared
visually. Ribotype patterns that differed by at least one band were
assigned to different ribotype groups, which were designated by
upper- and lower-case letters combined with a number.
Statistical analyses. The data are expressed as number (percentage),
mean±standard deviation (SD) or median (interquartile range). Either
the two-tailed unpaired Student’s t-test or the Mann–Whitney U-test
was used for comparisons of continuous variables with or without a
normal distribution, respectively, between the C. difficile toxigenic
culture-positive (confirmed) and -negative groups. We used the analysis
of variance (ANOVA) test and the Kruskal–Wallis test as the parametric
and non-parametric method, respectively, for the comparisons of
continuous variables between the three hospitals. For the nominal
variables, either Pearson’s x2-test or Fisher’s exact test was used in the
univariate analyses. We performed a multivariate logistic regression
analysis using the variables with a P-value less than 0.05 in the univariate
analyses to identify the risk factors of toxigenic culture-confirmed
hospital-onset CDI. The final regression model was expressed using the
odds ratio (OR) and 95% confidence interval (CI). A two-tailed
P,0.05 was considered to be statistically significant. All of the statistical
analyses in this study were performed using SPSS 20.0 software (SPSS).
RESULTS
Incidence of toxigenic culture-confirmed hospital-
onset CDI
The total incidence of toxigenic culture-confirmed hos-
pital-onset CDI in hospitalized adult patients was 2.70
cases per 10 000 patient-days. The incidence by hospital
was 2.90, 3.14 and 1.03 cases per 10 000 patient-days in
hospitals A (2500 beds), B (2000 beds) and C (1000 beds),
respectively. The percentage of severe toxigenic culture-
confirmed hospital-onset CDI cases was 3.1% (3 of 98
cases). The crude all-cause in-hospital mortality during the
enrolment admission and the attributed mortality of CDI
in 98 patients with toxigenic culture-confirmed hospital-
onset CDI were 3.1 and 0%, respectively.
Toxigenic C. difficile culture and PCR ribotype
Among the 348 stool specimens collected, 115 (33.0%)
were identified as growing C. difficile. Among the 115
anaerobically cultured isolates, toxigenic culture-confirmed
CDI was 98 (85.2%) cases. Among the 98 toxigenic-culture
positive specimens, there were 82 (83.7%) isolates of
the A+B+CDT2 strain, 11 (11.2%) isolates of the
A2B+CDT2 strain and 5 (5.1%) isolates of the
A+B+CDT+ strain.
Table 1. Results of PCR ribotyping analyses of the toxigenic C. difficile culture-positive stool samples
Kim’s ribotype UK ribotype* No. (%)
Total (N598) Hospital AD (N524) Hospital BD (N562) Hospital CD (N512)
A+B+CDT” strains
AB1 001 3 (3.1) 0 (0) 3 (4.8) 0 (0)
AB2 014 8 (8.3) 1 (4.2) 7 (11.3) 0 (0)
AB3 NM 9 (9.3) 1 (4.2) 5 (8.1) 3 (25.0)
AB4 161 1 (1.0) 0 (0) 1 (1.6) 0 (0)
AB5 002 1 (1.0) 0 (0) 1 (1.6) 0 (0)
AB6 012 2 (2.0) 1 (4.2) 1 (1.6) 0 (0)
AB8 163 1 (1.0) 0 (0) 0 (0) 1 (8.3)
AB9 NM 1 (1.0) 0 (0) 1 (1.6) 0 (0)
AB17 018 47 (48.1) 15 (62.5) 25 (40.3) 7 (58.4)
AB19 NM 1 (1.0) 0 (0) 1 (1.6) 0 (0)
AB22 NM 2 (2.0) 0 (0) 2 (3.3) 0 (0)
AB36 NM 1 (1.0) 0 (0) 1 (1.6) 0 (0)
AB45 NM 2 (2.0) 1 (4.2) 1 (1.6) 0 (0)
AB49 NM 2 (2.0) 0 (0) 2 (3.3) 0 (0)
AB50 NM 1 (1.0) 1 (4.2) 0 (0) 0 (0)
A”B+CDT” strains
aB 017 11 (11.2) 3 (12.5) 8 (12.9) 0 (0)
A+B+CDT+ strains
C2 078 2 (2.0) 0 (0) 1 (1.6) 1 (8.3)
C3 122 2 (2.0) 1 (4.2) 1 (1.6) 0 (0)
C17 267 1 (1.0) 0 (0) 1 (1.6) 0 (0)
*NM, Not matched.
DHospitals A, B and C have a total of 2500, 2000 and 1000 beds, respectively.
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PCR ribotyping analysis revealed 19 different patterns in
the 98 toxigenic strains. There were 15 patterns among the
A+B+CDT2 strains, one among the A2B+CDT2 strains,
and three among the A+B+CDT+ strains. All of the
A2B+CDT2 strains showed the same ribotype pattern,
which was identical to the pattern of the C. difficile 1470
strain (UK ribotype 017). UK ribotype 018 was the
predominant type (47 of 98 isolates, 48.1%). The most
common type in each of the three centres was UK ribotype
018. The percentage of UK ribotype 017 in hospitals A and
B was 12.5% and 12.9%, respectively. However, UK
ribotype 017 was not found in hospital C, which has a
relatively small number of beds. There were no hyperviru-
lent BI/NAP1/027 isolates (UK ribotype 027) identified in
this study (Table 1).
Comparison of clinical features between the
toxigenic culture-confirmed CDI group and the
culture-negative group
The mean age of the toxigenic culture-confirmed CDI group
was older than the toxigenic culture-negative group with
borderline statistical significance (64.6±14.4 vs 61.1±
16.4 years, P50.057), and there was no difference between
the two groups with regard to gender. The time between the
admission of the patient and the occurrence of diarrhoea
was significantly longer in the toxigenic culture-confirmed
CDI group than in the culture-negative group (34.1±20.1
vs 14.3±10.0 days, P50.013). The distributions of dia-
rrhoea-associated symptoms, including nausea, abdominal
pain and median maximal frequency of diarrhoea, were
similar between the two groups. Also, the blood pressure and
the clinical or laboratory findings of ileus, megacolon, body
temperature, white blood cell count, and serum creatinine
level at the time of loose stool sampling were not different
between the two groups (Table 2).
The toxigenic culture-confirmed CDI group had signific-
antly higher readmission within 3 months after hospital
discharge, and also had a higher rate of having had an
invasive procedure during the current admission than
the toxigenic culture-negative group (46.9 vs 30.0%,
P50.003, and 90.8 vs 75.2%, P,0.001, respectively). The
most common types of invasive procedure were blood
stream procedures, including central catheter insertion
and haemodialysis and/or continuous renal replacement
therapy, in both the toxigenic culture-confirmed CDI
group and the culture-negative group. There was no
significant difference in the frequency of invasive proced-
ure type between the two groups. The duration from first
admission in the previous 3 months to occurrence of
diarrhoea was not different between the two groups
(47.5±28.5 vs 49.5±24.0 days, P50.713). However, the
total admission duration before the first occurrence of
diarrhoea within the previous 3 months was significantly
longer in the toxigenic culture-confirmed CDI group than in
the culture-negative group (32.3±26.9 vs 19.8±17.0 days,
P,0.001) (Table 2).
Among the comorbid conditions, only the frequency
of cerebrovascular disease was significantly higher in the
toxigenic culture-confirmed CDI group than in the culture-
negative group (21.4 vs 11.2%, P,0.001). Having a positive
toxin EIA or toxin gene PCR with a history of CDI within
the previous 3 months was significantly higher in the toxi-
genic culture-confirmed CDI group than in the culture-
negative group (12.2 vs 0.4%, P,0.001). However, the
enteral nutrition history during the previous 3 months and
the mortality rate at the time of the current admission were
not significantly different between the two groups (Table 2).
We have summarized the comprehensive epidemiological
data of the three centres and marked the variables with
statistically significant difference in Table 2. Each centre
had different characteristics with regard to patient popu-
lation, number of beds, etc.
Characteristics of antibiotic use in the toxigenic
culture-confirmed CDI group and culture-negative
group
We compared the antibiotic exposure history within
3 months of the occurrence of diarrhoea between the two
groups. The frequency of previous total antibiotic exposure
history was significantly higher in the toxigenic culture-
confirmed CDI group than in the culture-negative group
(39.8 vs 27.6%, P,0.001). Also, the toxigenic culture-
confirmed CDI group had a significantly longer cumulative
total antibiotic exposure than the culture-negative group
(12.4±10.3 vs 4.9±2.7 days, P50.002). However, in the
analyses for each antibiotic class, only the carbepenems
showed significant differences between the two groups in
both the frequency of exposure history and the duration of
cumulative exposure (43.9 vs 34.0%, P50.017, and
10.6±7.6 vs 6.6±2.6 days, P50.020, respectively). There
were no significant differences between the two groups with
regard to broad-spectrum penicillin with an antipseudomo-
nal effect, third-generation cephalosporins with or without
the antipseudomonal effect, quinolones, intravenous glyco-
peptides, or clindamycin (Table 3).
Risk factors for toxigenic culture-confirmed CDI
In the multivariate logistic regression analysis, a history of
invasive procedure during the current admission (OR 7.3,
95% CI 2.0–27.1, P50.003) and laboratory (toxin EIA or
toxin gene PCR)-confirmed CDI history within the previous
3 months (OR 28.5, 95% CI 3.0–266.8, P50.003) were
independent risk factors for toxigenic culture-confirmed
CDI (Table 4).
DISCUSSION
The worldwide incidence of CDI has increased steadily
over the past decades, but recent data suggest that its
incidence and severity are now markedly increasing in
Western countries (O’Connor et al., 2009; Pe´pin et al.,
Hospital-onset CDI epidemiology in South Korea
http://jmm.sgmjournals.org 1545
Downloaded from www.microbiologyresearch.org by
IP:  128.134.207.84
On: Wed, 23 Dec 2015 00:51:02
Table 2. Comparison of demographic and clinical characteristics between the toxigenic culture-confirmed CDI group and the culture-negative group
Variable Total toxigenic
culture-confirmed
CDI group (N598)
Total toxigenic
culture-negative
group (N5250)
P* Hospital A
(N5106)D
Hospital B
(N5191)D
Hospital C
(N551)D
Age (years) 64.6±14.4 61.1±16.4 0.057a 57.8±14.7 63.4±16.3 66.2±15.0d
Gender, male 52 (53.1) 141 (56.4) 0.573b 67 (63.2) 96 (50.3) 30 (58.8)
Duration from admission to occurrence of diarrhoea (days) 34.1±20.1 14.3±10.0 0.013a 10.3±12.6 16.4±18.1 15.1±19.1d
Maximal frequency of diarrhoea (day21) 5 (4–7) 4 (4–7) 0.260c 5 (3–8) 4 (4–6) 5 (3–6)
Associated symptoms, yes
Abdominal pain 38 (38.8) 80 (32.0) 0.230b 26 (24.5) 15 (7.9) 12 (23.5)d
Fever (¢38 uC) 16 (16.3) 23 (9.2) 0.058b 12 (11.3) 12 (6.3) 15 (29.4)d
Nausea 7 (7.1) 18 (7.2) 0.985d 18 (17.0) 4 (2.1) 5 (5.9)d
Clinical and laboratory findings at the time of loose stool sampling
Systolic BP (mmHg) 117.5±18.2 116.7±17.5 0.702a 109.3±13.9 123.4±18.1 108.9±13.4d
Diastolic BP (mmHg) 72.5±12.5 73.2±40.8 0.858a 68.9±10.2 77.4±46.3 65.2±7.2d
Ileus, yes 11 (11.2) 19 (7.6) 0.279b 3 (2.8) 13 (6.8) 14 (27.5)d
Megacolon, yes 0 (0) 0 (0) – 0 (0) 0 (0) 0 (0)
WBC (mm23) 9787±7801 8799±6728 0.249a 8576±8332 9232±6681 9443±5628
Creatinine (mg dl21) 1.14±1.14 1.25±1.42 0.495a 0.96±0.66 1.24±1.44 1.62±1.78d
Body temperature (uC) 37.0±0.8 37.1±0.9 0.231a 36.9±0.7 37.1±0.9 37.2±1.0
Admission history within 3 months 0.003b
Initial hospitalization 52 (53.1) 175 (70.0) 65 (61.3) 127 (66.5) 35 (68.6)
Readmission 46 (46.9) 75 (30.0) 41 (38.7) 64 (33.5) 16 (31.4)
Duration from first admission in the previous 3 months to
occurrence of diarrhoea (days)
47.5±28.5 49.5±24.0 0.713a 64.0±22.1 43.1±24.9 44.1±23.8d
Total admission duration until occurrence of diarrhoea within
the previous 3 months (days)
32.3±26.9 19.8±17.0 ,0.001a 20.6±21.0 25.3±24.3 21.6±24.6
Invasive procedure during current admission, yes§ 89 (90.8) 188 (75.2) ,0.001b 77 (72.6) 164 (85.9) 36 (70.6)d
Urinary tracte 46/226 (20.5) 90/454 (19.8) 1/103 (1.0) 117/462 (25.3) 18/112 (16.1)
Blood streamf 60/226 (26.5) 136/454 (30.0) 52/103 (50.5) 121/462 (26.2) 23/112 (20.5)
Respiratory or pleural cavityg 31/226 (13.7) 50/454 (11.0) 5/103 (4.9) 58/462 (12.6) 18/112 (16.1)
Surgery
GI tract 6/226 (2.7) 28/454 (6.2) 20/103 (19.4) 11/462 (2.4) 3/112 (2.7)
Non-GI tract 36/226 (15.9) 67/454 (14.8) 18/103 (17.5) 58/462 (12.5) 27/112 (24.0)
Non-surgical GI tracth 47/226 (20.7) 80/454 (17.6) 7/103 (6.7) 97/462 (21.0) 20/112 (17.9)
Central nervous systemi 0/226 (0) 3/454 (0.6) 0/103 (0) 0/462 (0) 3/112 (2.7)
Comorbid diseases, yes
Any cancer in the last six years 24 (24.5) 67 (26.8) 0.645b 6 (5.7) 72 (37.7) 13 (25.5)d
Type 2 DM 27 (27.6) 67 (26.8) 0.903b 21 (19.8) 54 (28.3) 19 (37.3)
Heart disease 15 (15.3) 34 (13.6) 0.691b 3 (2.8) 36 (18.8) 10 (19.6)d
Hypertension 50 (51.0) 110 (44.0) 0.250b 39 (36.8) 90 (47.1) 31 (60.8)d
Renal insufficiency 13 (13.3) 20 (8.0) 0.135b 3 (2.8) 16 (8.4) 14 (27.5)d
Hepatic insufficiency 9 (9.2) 32 (12.8) 0.341b 14 (13.2) 18 (9.4) 9 (17.6)
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2004; Ricciardi et al., 2007). This multicentre prospective
observational study revealed that the incidence of toxigenic
culture-confirmed hospital-onset CDI in South Korea was
2.7 cases per 10 000 patient-days. The percentage of these
cases having severe CDI was relatively low (3.1%). To our
knowledge, this is the first multicentre prospective
epidemiological study to include PCR ribotyping analysis
and to assess the risk factors for hospital-onset CDI in
South Korea. In another Korean study, performed in a
single hospital, the incidence of healthcare-associated CDI,
defined as the number of cases for which C. difficile cultured
from stool specimens contained toxin genes confirmed by
multiplex PCR or by a positive toxin A & B EIA among
patients who developed diarrhoea with onset at least 3 days
after admission or within 2 months of the most recent
hospital discharge, was 7.16 cases per 10 000 patient-days
(Kim et al., 2013a). There have also been several recent
studies that have reported that hospital-acquired CDI has
significantly increased in South Korea (Byun et al., 2009; Lee
et al., 2010). The most recent multinational data from a
Europe-wide, hospital-based survey reported a mean
incidence of healthcare-associated CDI of 4.1 cases per
10 000 patient-days (Bauer et al., 2011). However, this
incidence was significantly variable between countries,
ranging between 0.0 and 36.3 (Bauer et al., 2011). A recent
prospective surveillance study in Canada showed that the
incidence of healthcare-associated CDI was 6.5 cases per
10 000 patient-days between 2002 and 2007 (Gravel et al.,
2009). In the USA, the healthcare facility-onset and
-associated CDI incidence was 8.5 cases per 10 000 patient-
days in 2006 (Dubberke et al., 2010). The relatively low
incidence in our study compared with those in other studies in
Korea andWestern countries may be due to ourmore accurate
definition of laboratory-confirmed CDI and narrowed
restriction to only toxigenic culture-positive cases. In addition,
the different rates of CDI between centres could be because of
the difference in characteristics of patients among centres.
Shin et al. (2008a, b) have reported that toxin A-negative
and toxin B-positive (tcdA2tcdB+) strains were prevalent
in Korea from 2003, and that this strain constituted 27%
of toxigenic strains in 2005, which is much higher than
reported in other countries, and that this may have been
responsible for the high rate of PMC in both a multicentre
and a single-centre retrospective study. However, the
A2B+CDT2 variant strain was only present in 11.2% of
the 98 toxigenic isolates in our multicentre prospective
study. Recently, Kim et al. (2010) have reported that binary
toxin CDT-producing strains are not rare (7.1%) in Korea.
In the present study, there were five CDT-producing
strains (5.1%) among the toxigenic isolates, similar to the
results of the previous study (Kim et al., 2010). The most
prevalent PCR ribotype was UK 018, and all of the
A2B+CDT2 strains showed only one pattern (UK 017). In
contrast to previous Korean studies, this study had a lower
prevalence of the A2B+CDT2 variant strain. We did not
identify the hypervirulent UK ribotype 027 strains in
our study, although we did identify another binaryT
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toxin-producing strain, UK ribotype 078. A European
multinational hospital-based survey (Bauer et al., 2011)
has also identified UK ribotype 018 as the predominant
type associated with complicated disease outcome in an
area where UK ribotype 027 was absent, similar to our
results.
Our study has the unique strength of having prospective
data collection from multiple centres and the most accurate
method of CDI diagnosis of toxigenic culture-confirmed
cases, instead of using an EIA with a low sensitivity of 63–
73%, in contrast with other Korean CDI epidemiological
and surveillance studies (Delme´e et al., 2005; Peterson et al.,
2007). We applied identical definitions and used the same
data collection method to measure many of the clinical
variables. In addition, the microbiological diagnoses for
CDI were uniformly performed using a standardized
protocol in one central laboratory. We also used alcohol-
shocked enrichment stool specimens in anaerobic C.
difficile culture to improve the sensitivity of its growth
(Riley et al., 1987).
The independent risk factors for the development of
hospital-onset CDI in our study were (1) experience of an
invasive procedure during the current admission period, and
(2) a laboratory (toxin EIA or toxin gene PCR)-confirmed
Table 3. Comparisons of antibiotic exposure history and cumulative duration within 3 months from occurrence of diarrhoea between
toxigenic culture-confirmed CDI group and culture-negative group
Variable Toxigenic culture-confirmed
CDI group (N598)
Toxigenic culture-negative
group (N5250)
P
Any antibiotics
Yes 39 (39.8) 69 (27.6) ,0.001a
Cumulative duration (days) 12.4±10.3 4.9±2.7 0.002b
Broad-spectrum penicillins with antipseudomonal effect
Yes 45 (45.9) 118 (47.2) 0.586a
Cumulative duration (days) 6.6±5.6 6.0±5.5 0.623b
Third-generation cephalosporins without antipseudomonal effect
Yes 39 (39.8) 97 (38.8) 0.407a
Cumulative duration (days) 3.2±2.4 3.9±2.7 0.401b
Third-generation cephalosporins with antipseudomonal effect
Yes 18 (18.4) 30 (12.0) 0.056a
Cumulative duration (days) 1.8±0.9 1.2±0.1 0.221b
Carbapenems
Yes 43 (43.9) 85 (34.0) 0.017a
Cumulative duration (days) 10.6±7.6 6.6±2.6 0.020b
Quinolones
Yes 49 (50.0) 134 (53.6) 0.813a
Cumulative duration (days) 6.9±4.7 6.5±5.9 0.720b
Intravenous glycopeptides
Yes 39 (39.8) 88 (35.2) 0.149a
Cumulative duration (days) 8.0±3.3 5.4±3.0 0.102b
Clindamycin
Yes 2 (2.0) 12 (4.8) 0.299c
Cumulative duration (days) 0.3±0.1 0.8±0.3 0.336b
Data are expressed as either mean±SD or number (percentage). aPearson’s x2-test, bindependent sample Student’s t-test, cFisher’s exact test.
Table 4. Multivariate logistic regression analysis to identify risk factors of toxigenic culture-confirmed hospital-onset CDI
Independent variables, yes OR 95% CI P
Duration from admission to occurrence of diarrhoea .2 weeks 1.1 0.6–2.2 0.737
Readmission within 3 months 1.6 0.9–3.0 0.139
Total admission duration during previous 3 months to occurrence of diarrhoea .3 weeks 1.4 0.6–2.9 0.417
Invasive procedure during current admission 7.3 2.0–27.1 0.003
Cerebrovascular disease 1.0 0.5–2.2 0.973
Laboratory (toxin EIA or toxin gene PCR)-positive CDI history within previous 3 months 28.5 3.0–266.8 0.003
Exposure history of carbapenems within 3 months from occurrence of diarrhoea 1.1 0.6–1.9 0.847
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CDI history. Previously, non-surgical gastrointestinal
procedures had been identified as risk factors of C.
difficile-associated diarrhoea (Bignardi, 1998). However,
we did not find an independent relationship between any
specific type of invasive procedure and the development of
hospital-onset CDI. Unlike the studies from Western
countries that had reported IBD as an emerging risk factor
for CDI, there were no CDI patients with comorbid IBD
in our study. Another nationwide study in South Korea
had reported the rate of CDI patients with IBD to be as
low as 2.2% (30 of 1367) (Kim et al., 2013b). In contrast
with the previous reports, we did not find the independent
relation between the recent exposure history or cumulat-
ive duration of any specific antibiotic, including the well-
known CDI-triggering antibiotics such as clindamycin,
and the development of hospital-onset CDI (Freeman
et al., 2010; Lo Vecchio & Zacur, 2012). Although the
recent exposure history and cumulative duration of any
antibiotics and carbepenems were significantly higher and
longer in the toxigenic culture-confirmed CDI group than
in the culture-negative group in the univariate analyses,
the final multivariate regression model revealed the
stronger effect of invasive procedure and past history of
a laboratory-confirmed CDI. The frequency of CDI in
patients who had not recently received antibiotic treat-
ment was higher in our study than in other studies (Kim
et al., 2013a). Hospital-onset toxigenic culture-confirmed
CDI developed in as many as 60% of patients who had
not received any antibiotics within the previous 3 months.
Our results might reflect the recent epidemiological
change in CDI and the importance of C. difficile spore
acquisition through the hospital environment rather than
the disruption of colonic normal flora by antibiotics in the
development of hospital-onset CDI (Lessa et al., 2012).
Therefore, active and continuous implementation of
environmental control polices may have to be emphasized
to decrease the incidence of hospital-onset CDI.
This study has several limitations. First, we were unable to
perform endoscopic evaluation in all of our patients to
assess the exact severity of each CDI case. Therefore, it is
possible that we may have underestimated the number of
severe CDI cases. Second, we did not collect the history of
gastric acid suppressant use, including exposure to proton
pump inhibitors, which is proposed as one of the risk
factors for CDI (Freeman et al., 2010). However, a recent
study found no association between gastric acid suppres-
sants and a more severe course of CDI (Henrich et al.,
2009). It is still a matter of ongoing debate as to whether
there is a causal association between gastric acid suppres-
sants and CDI (Freeman et al., 2010; Lo Vecchio & Zacur,
2012). Third, our study only used tertiary hospitals with at
least 1000 beds; the study subjects from these hospitals tend
to be more severely ill than patients that are admitted to
smaller hospitals. Therefore, this incidence of 2.7 cases per
10 000 patient-days might be overestimated compared
with the general nationwide surveillance data. Finally,
the ratio of toxigenic culture-confirmed CDI (N598) to
antibiotic-associated diarrhoea, that is, total collected loose
stool specimens (N5348), was relatively high at 28.2%.
Because two centres should send the stool samples to one
central laboratory, they possibly would drop the suspected
CDI cases, and with this, CDI incidence could be
underestimated, especially in hospital C with the relative
low incidence. However, despite these limitations, this
well-designed and prospectively performed study provides
important information concerning the clinical impact of
CDI in South Korea without epidemics of hypervilurent
UK ribotype 027 strains.
In conclusion, the incidence of toxigenic culture-confirmed
hospital-onset CDI in South Korea was 2.7 cases per 10 000
patient-days. Although the incidence and clinical features
of hospital-onset CDI are, overall, respectively low and
milder than those in Western countries, the considerable
burden of CDI suggests that South Korea is no longer a safe
area with regard to CDI. Therefore, preventive strategies,
including active immunization, should be considered to
decrease the mortality and morbidity caused by CDI and to
lower healthcare costs associated with hospital-acquired
CDI, especially in patients with the identified risk factors.
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